: This study investigated the clinical outcome of neoadjuvant androgen deprivation therapy followed by high dose rate brachytherapy (HDR-BT, called NEH) with external beam radiotherapy (EBRT) in high-risk prostate cancer (PCa) patients in our institution. : From 2007 to 2012, 192 high-risk PCa patients underwent neoadjuvant treatment-EBRT-NEH ( n = 192). Relations between clinical factors (prostate-specific antigen; PSA, cT stage, Gleason score) and biochemical recurrence were retrospectively analyzed. : The 5- and 7-year overall survival rates were 97.9 and 91.1%. By PSA levels (PSA 20 ng/ml, 20 ng/ml < PSA≤50 ng/ml and PSA > 50 ng/ml), 5-year biochemical recurrence-free survival rates were 85.7, 84.7 and 54.5%, respectively. There were no significant differences between biochemical recurrence and cT stage or Gleason score. : We found that NEH can contribute to better biochemical recurrence free survival of high-risk PCa patients with PSA below 50 ng/ml. High-risk PCa patients with PSA over 50 ng/ml may require more aggressive local or systemic treatment.
Japanese journal of clinical oncology. 2018 Nov 23 [Epub ahead of print]
Suguru Shirotake, Soichi Makino, Kenjiro Suzuki, Ryuichiro Araki, Takeo Kosaka, Koshiro Nishimoto, Masafumi Oyama, Shingo Kato
Department of Uro-Oncology, Saitama Medical University International Medical Center, Saitama, Japan., Department of Radiation Oncology, Saitama Medical University International Medical Center, Saitama, Japan., Community Health Science Center, Saitama Medical University, Saitama, Japan., Department of Urology, Keio University School of Medicine, Tokyo, Japan.